Venus Medtech (Hangzhou) Inc.

2017/11/29 14:45


AsiaNet 71278 (1923)

【杭州(中国)2017年11月28日PR Newswire=共同通信JBN】


回収可能なVenusA Plusバルブシステムの初の人体移植が、2017年11月23日、浙江大学医学部第2付属病院で成功裏に終了した。

Photo -

浙江大学医学部(SAHZU)部長のワン・ジアンアン教授は、中国が回収可能な経カテーテル大動脈弁の初の人体移植を成功裏に終了したと発表した。これはVenus Medtechにとって新たなマイルストーンであり、同社は回収可能なインターベンショナル心臓弁システムを提供する能力を持つ初の企業となる。



ワン教授は「浙江大学医学部(SAHZU)の医療チームは、心臓弁製品を研究、開発、製造するため、浙江省の心臓弁研究所およびVenus MedtechのR&Dチームと緊密に協力してきた。このコラボレーションは、VenusA-Valveとともに始まり、VenusA Plusの成功につながった」と語った。同博士は続けて、「製品は次世代のTAVRバルブであり、リリース、回収可能な安定性、制御性、通過性能の意味で良好な性能を発揮し、臨床上のアプリケーションに至る大きな可能性を提供する」と述べた。

VenusA Plusの人体移植の成功は、中国初のTAVR弁であるVenusA-Valveの発売後4カ月で実施された。Venus Medtechのジー・ゼンジュン最高経営責任者(CEO)は「Venus Medtechは引き続き技術的な飛躍的進歩を達成した。われわれは、イノベーションおよび現在行っている患者に奉仕する約束に会社の強力な能力を発揮しつつ、今後、さらに革新的な製品を展開する計画だ」と語った。

ソース:Venus Medtech (Hangzhou) Inc.

China Successfully Completes the Country's First Human Implantation of a Retrievable Transcatheter Aortic Valve


HANGZHOU, China, Nov. 28, 2017 /PRNewswire=KYODO JBN/ --

- The success of the procedure unleashes a new era for retrievable

interventional cardiac valve technology in China

The first human implantation of the VenusA Plus retrievable valve system was

completed successfully at the Second Affiliated Hospital of Zhejiang University

School of Medicine (SAHZU) on November 23, 2017.

Photo -

Prof. Wang Jian'an, president of SAHZU, announced that China has completed its

first successful human implantation of a retrievable transcatheter aortic

valve. It marks another milestone for Venus Medtech, becoming China's first

company capable of providing a retrievable interventional cardiac valve system.

The 76-year-old female patient who was operated on using the system had been

diagnosed with severe aortic valve stenosis and defined as a high-risk surgical

patient. The heart team discussed and defined the patient's anatomical features

as a bicuspid aortic valve and asymmetric calcification, which raised the risk

of dislocation during the valve implantation. They were of the opinion that the

retrievable system would be the best fit for the patient.

The retrievable system allows the valve to withdraw and reposition after

release, avoiding adverse events as a result of a poor implant position and

mismatch of the implanted valve, including valve translocation, severe

paravalvular leakage, a negative impact on the bicuspid aortic valve and high

degree atrioventricular block caused by conduction bundle compression. The

system also reduces the complexity of the procedure, which, in turn, helps to

promote the adoption and application of TAVR technology.

"SAHZU's medical team has been closely working with Zhejiang Province's Cardiac

Valve Research Institute and Venus Medtech's R&D team to study, develop and

produce the heart valve products. The collaboration began with the VenusA-Valve

and has led to the success for VenusA Plus," professor Wang added. "The product

is a next-generation TAVR valve that delivers good performance in terms of

release, retrievable stability, controllability and passing ability, thus

offering great potential when it comes to clinical applications."

The successful human implantation of VenusA Plus took place just four months

after the launch of China's first TAVR valve VenusA-Valve. "Venus Medtech has

continuously achieved technological breakthroughs," explained Venus Medtech CEO

Zi Zhenjun. "We plan to roll out more innovative products going forward,

demonstrating the company's strong competence in innovation and its ongoing

commitment to serving patients."

SOURCE: Venus Medtech (Hangzhou) Inc.